会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • CRYSTALLINE MICROPOWDER PARTICLES
    • 晶体微波颗粒
    • US20100160634A1
    • 2010-06-24
    • US12601150
    • 2008-05-20
    • Masahiro AkimotoToshikazu KomagataMotohiro ShirakiAkihiro Ando
    • Masahiro AkimotoToshikazu KomagataMotohiro ShirakiAkihiro Ando
    • C07D489/08
    • A61K9/1688A61K9/2018A61K31/485C07D489/08
    • Crystalline particles of N-(17-cyclopropylmethyl-4,5α-epoxy-3,14-dihydroxy-morphinan-6β-yl)-phthalimide or a pharmaceutically acceptable salt thereof are disclosed. The crystalline particles have a particle diameter distribution in which a particle diameter (D50) at the point where cumulative frequency of volume distribution cumulatively calculated from particles having a smaller diameter reaches 50% is within a range of 1 to 30 μm, and a particle diameter (D90) at the point where cumulative frequency of volume distribution cumulatively calculated from particles having a smaller diameter reaches 90% is not more than 90 μm, which crystalline particles have a degree of crystallinity of not less than 80%. By the crystalline particles, bioavailability of the active substance may be increased while ensuring storage stability of the compound.
    • 公开了N-(17-环丙基甲基-4,5α-环氧-3,14-二羟基 - 吗啡喃-6'-基) - 邻苯二甲酰亚胺或其药学上可接受的盐的结晶颗粒。 结晶粒子具有粒径分布,其中由具有小直径的颗粒累积计算的体积分布的累积频率达到50%的点处的粒径(D50)在1至30μm的范围内,并且粒径 (D90)在由具有较小直径的颗粒累积计算的体积分布的累积频率达到90%的点处不超过90μm,该结晶颗粒的结晶度不小于80%。 通过结晶颗粒,可以提高活性物质的生物利用度,同时确保化合物的储存稳定性。
    • 2. 发明授权
    • Crystalline micropowder particles
    • 结晶微粉颗粒
    • US08198446B2
    • 2012-06-12
    • US12601150
    • 2008-05-20
    • Masahiro AkimotoToshikazu KomagataMotohiro ShirakiAkihiro Ando
    • Masahiro AkimotoToshikazu KomagataMotohiro ShirakiAkihiro Ando
    • C07D489/08
    • A61K9/1688A61K9/2018A61K31/485C07D489/08
    • Crystalline particles of N-(17-cyclopropylmethyl-4,5α-epoxy-3,14-dihydroxy-morphinan-6β-yl)-phthalimide or a pharmaceutically acceptable salt thereof are disclosed. The crystalline particles have a particle diameter distribution in which a particle diameter (D50) at the point where cumulative frequency of volume distribution cumulatively calculated from particles having a smaller diameter reaches 50% is within a range of 1 to 30 μm, and a particle diameter (D90) at the point where cumulative frequency of volume distribution cumulatively calculated from particles having a smaller diameter reaches 90% is not more than 90 μm, which crystalline particles have a degree of crystallinity of not less than 80%. By the crystalline particles, bioavailability of the active substance may be increased while ensuring storage stability of the compound.
    • 公开了N-(17-环丙基甲基-4,5α-环氧-3,14-二羟基 - 吗啡喃-6'-基) - 邻苯二甲酰亚胺或其药学上可接受的盐的结晶颗粒。 结晶粒子具有粒径分布,其中由具有小直径的颗粒累积计算的体积分布的累积频率达到50%的点处的粒径(D50)在1至30μm的范围内,并且粒径 (D90)在由具有较小直径的颗粒累积计算的体积分布的累积频率达到90%的点处不超过90μm,该结晶颗粒的结晶度不小于80%。 通过结晶颗粒,可以提高活性物质的生物利用度,同时确保化合物的储存稳定性。
    • 9. 发明授权
    • Method for surface-treating substrate and substrate surface-treated by
the method
    • 通过该方法表面处理基材和表面处理的基材的方法
    • US5800693A
    • 1998-09-01
    • US771154
    • 1996-12-20
    • Masahiko KakizakiMasahiro Akimoto
    • Masahiko KakizakiMasahiro Akimoto
    • C25D11/30
    • C25D11/30
    • A method for surface-treating a substrate made of a magnesium-based metal material is disclosed, which includes immersing the substrate in an electrolyte composed of an aqueous solution containing at least one component selected from the group consisting of hydroxides, carbonates and bicarbonates of alkali metals or alkali earth metals, and a film-forming stabilizer, and conducting an electrolysis to form an anodic oxide film on a surface of the substrate. The film-forming stabilizer includes one component selected from salts of mineral acids, fluorides, silicates and silicofluorides and an additional component selected from ethylene glycol, trihydroxypropane, dihydroxyethyl ether and sodium hydroxybenzoate. Further, in accordance with the present invention, there is provided the substrate which is surface-treated by the method.
    • 公开了一种用于表面处理由镁基金属材料制成的衬底的方法,其包括将衬底浸入由含有至少一种选自氢氧化物,碳酸盐和碱金属碳酸盐的组分的水溶液组成的电解质中 金属或碱土金属和成膜稳定剂,并且在基材的表面上进行电解以形成阳极氧化膜。 成膜稳定剂包括选自无机酸,氟化物,硅酸盐和硅氟化物的盐的一种组分和选自乙二醇,三羟基丙烷,二羟乙基醚和羟基苯甲酸钠的另外的组分。 此外,根据本发明,提供了通过该方法进行表面处理的基板。
    • 10. 发明授权
    • Medical treatment sewing machine
    • 医疗缝纫机
    • US4437465A
    • 1984-03-20
    • US344774
    • 1982-02-01
    • Reishi NomotoMasahiro AkimotoMasayoshi Takahashi
    • Reishi NomotoMasahiro AkimotoMasayoshi Takahashi
    • A61B17/04D05B81/00A61B17/06
    • D05B81/00A61B17/0491
    • A suturing instrument for a surgical operation includes a suturing portion having a base, a vertically reciprocating needle holder carrying a needle with an upper thread, a device for supplying a predetermined amount of the upper thread to the needle and a loop taker supported in the base for turnable movement relative thereto and operative for catching a thread loop formed on the needle. The device for supplying the upper thread, the loop taker and the needle holder are activated for sequential operation by a control portion of the instrument which includes a fluid drive device connected to the suturing portion and including a plurality of hydraulic cylinders. The control portion is activated by a manually operated switch which actuates an electric circuit and a switching device operating a plurality of the cylinders for sequentially imparting the reciprocating movements to the needle, the loop taker and the thread supplying device.
    • 用于外科手术的缝合器具包括具有基部的缝合部分,承载带有面线的针的垂直往复运动的针保持器,用于向针提供预定量的面线的装置以及支撑在基部中的环接受器 用于相对于其可转动的运动,并且用于捕捉形成在针上的螺纹环。 用于供应面线,回路接收器和针保持器的装置被启动以由仪器的控制部分顺序操作,该装置的控制部分包括连接到缝合部分并且包括多个液压缸的流体驱动装置。 控制部分由手动操作的开关激活,该开关致动电路和操作多个气缸的开关装置,以顺序地向针,回路接收器和线供给装置施加往复运动。